Key protein behind chemotherapy resistance in colorectal cancer identified

Researchers have identified a key protein responsible for chemotherapy resistance in colorectal cancer patients treated with 5-fluorouracil (5-FU), one of the most widely used chemotherapeutic agents. Cancer cells develop resistance to this cornerstone treatment through repeated exposure, allowing tumors to adapt and evade therapy. This breakthrough discovery could lead to new therapeutic strategies to overcome drug resistance and improve outcomes for colorectal cancer patients. Understanding the mechanisms behind treatment resistance is crucial for developing combination therapies and personalized treatment approaches. The findings may enable oncologists to better predict which patients are at risk for resistance and adjust treatment plans accordingly.